285.25

-0.7%↓

CAT

594.6

-0.23%↓

RTX

171.72

+0.18%↑

GEV.US

624.84

+0.55%↑

200.4

-2.84%↓

285.25

-0.7%↓

CAT

594.6

-0.23%↓

RTX

171.72

+0.18%↑

GEV.US

624.84

+0.55%↑

200.4

-2.84%↓

285.25

-0.7%↓

CAT

594.6

-0.23%↓

RTX

171.72

+0.18%↑

GEV.US

624.84

+0.55%↑

200.4

-2.84%↓

285.25

-0.7%↓

CAT

594.6

-0.23%↓

RTX

171.72

+0.18%↑

GEV.US

624.84

+0.55%↑

200.4

-2.84%↓

285.25

-0.7%↓

CAT

594.6

-0.23%↓

RTX

171.72

+0.18%↑

GEV.US

624.84

+0.55%↑

200.4

-2.84%↓

Начало・Списък с акции・Ocugen Inc

Ocugen Inc

Затворен

1.19 -0.83

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.19

Максимум

1.21

Ключови измерители
By Trading Economics
Приходи	-5.3M -20M
Продажби	379K 1.8M
EPS	-0.07
Марж на печалбата	-1,144.463
Служители	95
EBITDA	-4.9M -18M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+678.69% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-106M 375M
Предишно отваряне	2.02
Предишно затваряне	1.19

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

0.6818 / 0.74 Подкрепа & съпротива

Ocugen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.12.2025 г., 22:13 ч. UTC

Печалби

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9.12.2025 г., 21:40 ч. UTC

Печалби

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9.12.2025 г., 18:51 ч. UTC

Придобивния, сливания и поглъщания

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9.12.2025 г., 16:57 ч. UTC

Значими двигатели на пазара

Clear Secure Rises on Medicare Identity Verification Contract

9.12.2025 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9.12.2025 г., 23:46 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings Stake in Lenovo Now at 32.34%

9.12.2025 г., 23:45 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9.12.2025 г., 23:44 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9.12.2025 г., 23:43 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9.12.2025 г., 23:43 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9.12.2025 г., 23:35 ч. UTC

Пазарно говорене

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9.12.2025 г., 22:42 ч. UTC

Печалби

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

9.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.12.2025 г., 21:48 ч. UTC

Пазарно говорене

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9.12.2025 г., 20:28 ч. UTC

Пазарно говорене

Oil Futures Decline for Second Straight Session -- Market Talk

9.12.2025 г., 20:27 ч. UTC

Придобивния, сливания и поглъщания

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9.12.2025 г., 20:27 ч. UTC

Придобивния, сливания и поглъщания

Teck Reports Voting Results From Special Meeting of Hldrs

9.12.2025 г., 20:26 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9.12.2025 г., 20:21 ч. UTC

Пазарно говорене

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9.12.2025 г., 19:52 ч. UTC

Печалби

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9.12.2025 г., 19:17 ч. UTC

Печалби

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.12.2025 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

9.12.2025 г., 17:11 ч. UTC

Печалби

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Ocugen Inc Прогноза

Ценова цел

By TipRanks

678.69% нагоре

12-месечна прогноза

Среден 9.5 USD 678.69%

Висок 15 USD

Нисък 7 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocugen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Ocugen Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.6818 / 0.74Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.